Investment case
Skye Bioscience, Inc.
SKYE · 2 developments mapped · last assessed 2026-08-18
Market Ontology has mapped 2 macro, policy, and market developments to Skye Bioscience, Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for SKYE yet, so no modelled value is shown. The SKYE valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run SKYE on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Skye Bioscience, Inc. Announces Proposed Acquisition of Redx Pharma Limited
Direct impact of delisting notice and uncertainty surrounding acquisition financing/completion.
· Moves risk premium for equity, probability of successful acquisition, liquidity discount
- Open question
Skye Bioscience, Inc. to Acquire Redx Pharma Limited ($125M)
Direct acquisition of a complementary asset, financed by new capital, leading to potential dilution and integration risks but also pipeline expansion.
· Moves future r&d success rates, synergy realization, cost of capital (wacc due to increased risk/financing)
What changed, by assumption
- 2026-08-18Skye Bioscience, Inc. Announces Proposed Acquisition of Redx Pharma Limited
- 2026-08-14Skye Bioscience, Inc. to Acquire Redx Pharma Limited ($125M)
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-15 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-15 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-15 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-18 | Skye Bioscience, Inc. Announces Proposed Acquisition of Redx Pharma Limited | Bearish | 1-5d | 0.90 |
| 2026-08-14 | Skye Bioscience, Inc. to Acquire Redx Pharma Limited ($125M) | mixed | 3-12m | 0.60 |